A randomized trial of recombinant human interleukin-1 I following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer

Biology of Blood and Marrow Transplantation

Volumn 4, Issue 3, 1998, Pages 134-141

  Vredenburgh, James J ^a   Hussein, Atif ^b   Fisher, David ^c   Hoffman, Maureane ^a   Elkordy, Maha ^a   Rubin, Peter ^a   Gilbert, Colleen ^a   Kaye, James A ^d   Dykstra, Kevin ^d   Loewy, John ^d   Peters, William P ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Colombia Health Care ^*  (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d PFIZER INC   (United States)

^e KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Interleukin 11; rhil 11; Thrombocytopenia

Indexed keywords

INTERLEUKIN 11; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-11; MIDDLE AGED; RECOMBINANT PROTEINS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0032246170     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.1998.v4.pm9923411     Document Type: Article

References (22)

1. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281, 1984.
2. Budman DR, Wood W, Henderson IC, Korzun A, Cooper R, Younger J, Hart R, Moore A, Ellerton J, Norton L, Ferree C, Colangelo A, McIntyre O: Initial findings of CALGB 8541: a dose and dose intensity trial of cyclophosphamide (C), doxorubicin (A), and 5-fluorouracil (F) as adjuvant treatment of stage II, node +, female breast cancer. Proc Am Soc Clin Oncol 11:51, 1992. [abstr]
3. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marts LB, Winer E, Kurtzberg J, Bast RC, Jones R, Shpall E, Wu K, Rosner G, Gilbert C, Mathias B, Coniglio D, Petras W, Henderson C, Norton L, Weiss RB, Budman D, Hurd D: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132, 1993.
4. Karolak L, Chandra A, Khan W, Marks B, Petras W, Peters W, Greenberg C, Hannnn Y: High-dose chemotherapy-induced platelet defect: inhibition of platelet signal transduction pathways. Mol Pharmacol 43:37, 1993.
5. Paul SR, Bennett F, Calvetti JA, Kelleher K, Wood CR, O'Hara Jr RM, Leary AC, Sibley B, Clark SC, Williams DA, Yang Y-C: Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA 87:7512, 1990.
6. Yonemura Y, Kawakita M, Masuda T, Fujimoto K, Kato K, Takatsuki K: Synergistic effects of interleukin 3 and interleukin 11 on murine megakaryopoiesis in serum-free culture. Exp Hematol 20:1011, 1992.
7. Teramura M, Kobayashi S, Hoshino S, Oshimi K, Mizoguchi H: Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood 79:327, 1992.
8. Bruno E, Briddell RA, Cooper RJ, Hoffman R: Effects of recombinant interleukin 11 on human megakaryocyte progenitor cells. Exp Hematol 19:378, 1991.
9. Goldman SJ: Preclinical biology of interleukin 11: a multifunctional hematopoietic cytokine with potent thrombopoietic activity. Stem Cells 13:462, 1995.
10. Champlin R, Mehra R, Kaye J, Woodin MB, Wood J, Andersson B, van Besien K, Gajewski J, Przepiorka D, Deisseroth AB: Phase I study of recombinant human interleukin-11 following autologous BMT in patients with breast cancer. Proc Am Soc Clin Oncol 13:100, 1994. [abstr]
11. Romp KG, Peters WP, Hoffman M: Reticulated platelet counts in patients undergoing autologous bone marrow transplantation: an aid in assessing marrow recovery. Am J Hematol 46:319, 1994.
12. Ault KA, Rinder HM, Mitchell J, Carmody MB, Vary CPH, Hillman RS: The significance of platelets with increased RNA content (reticulated platelets): a measure of the rate of thrombopoiesis. Am J Clin Pathol 98:637, 1992.
13. Ault KA, Mitchell J, Knowles C, Clendaniel A, Egan A, Loewy J, Garnick MB, Kaye JA: Recombinant human interleukin eleven (NEUMEGA™ rhIL-11 growth factor) increases plasma volume and decreases urine sodium excretion in normal human subjects. Blood 84:276a, 1994. [abstr]
14. Dykstra K, Rogge H, Stone A, Loevy J, Schvertschlag U: Effect of diuretic treatment on rhIL-11-induced salt and water retention. Blood 88 (Suppl. 1):346a, 1996. [abstr]
15. Gordon MS, Nemunaitis J, Hoffman R, Paquette RL, Rosenfeld C, Manfreda S, Isaacs R, Nimer SD: A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 85:3066, 1995.
16. Rintala E, Pulkki K, Mertsola J, Nevalainen T, Nikoskelainen J: Endotoxin, interleukin-6 and phospholipase-A2 as markers of sepsis in patients with hematological malignancies. Scand J Infect Dis 27:39, 1995.
17. Dinarello CA: Biologic basis for interleukin-1 in disease. Blood 87:2095, 1996.
18. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA: High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity, and histologic findings. JAMA 256:3117, 1986.
19. Silgals RM, Ahlgren JD, Neefe JR, Rothman J, Rudnick S, Galicky P, Schein PS: A phase II trial of high-dose intravenous interferon alpha-2 in advanced colorectal cancer. Cancer 54:2257, 1984.
20. Dutcher JP, Schiffer CA, Aisner J, Wiernik PH: Alloimmunization following platelet transfusion: the absence of a dose-response relationship. Blood 57:395, 1981.
21. Tepler I, Elias L, Smith II JW, Hussein M, Rosen G, Chang AY-C, Moore JO, Gordon MS, Kuca B, Beach KJ, Loewy JW, Garnick MB, Kaye JA: A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87:3607, 1996.
22. Isaacs C, Robert NJ, Bailey FA, Schuster MW, Overmoyer B, Graham M, Cai B, Beach KJ, Loewy JW, Kaye JA: A randomized, placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol. In press.